A New Hope for Treatment-Resistant Depression

If you’re struggling with depression that hasn’t responded to traditional medications, you’re not alone. Millions of people face treatment-resistant depression (TRD), where standard antidepressants fail to provide relief. At Ketavita, we offer Spravato® REMS nasal spray, an FDA-approved treatment specifically designed to help when other therapies haven’t worked.

Spravato works differently than conventional antidepressants, providing rapid relief for depressive symptoms and giving patients new hope for recovery.

Safe and Supervised

Proven Reduction

Rapid Symptom Relief

FDA-Approved

Request a Consultation

What is Spravato®?

SPRAVATO® (esketamine) is an FDA-approved prescription nasal spray designed to help adults struggling with certain types of severe depression. It offers a breakthrough option when traditional medications are not enough.

Conditions SPRAVATO® Is Approved to Treat:

Treatment-Resistant Depression (TRD)
For adults who have not achieved adequate relief after trying at least two or more antidepressant therapies.

Major Depressive Disorder (MDD) with Acute Suicidal Ideation or Behavior
For individuals experiencing severe depressive episodes with suicidal thoughts or behaviors, offering a fast-acting treatment option when immediate support is critical.

Why SPRAVATO® Is Different

Unlike traditional antidepressants, which often take weeks to show results, clinical studies show that SPRAVATO® can improve symptoms in as little as 24 hours. By targeting different pathways in the brain, SPRAVATO® offers new hope for patients in urgent need of relief.

Fast-Acting Relief

  • Many patients feel noticeable improvements within hours to days of their first treatment.

Promotes Neuroplasticity

  • Encourages the brain to create new neural connections, helping to “reset” disrupted thought patterns.

Targets Glutamate

  • By modulating glutamate levels, Spravato helps restore balance to brain pathways involved in mood regulation.

Why SPRAVATO® May Be More Effective Than Traditional Antidepressants

Higher Response Rates

While traditional antidepressants typically show a 40–60% response rate, clinical trials demonstrate that SPRAVATO® (esketamine) can achieve response rates of up to 70% (Popova et al., American Journal of Psychiatry, 2019).

Rapid Relief

Conventional antidepressants often take 4–6 weeks before patients notice meaningful improvements. In contrast, SPRAVATO® may provide symptom relief within as little as 24 hours, as documented in clinical studies (BMC Psychiatry, 2022).

Greater Chances of Remission

Sustained remission rates for traditional antidepressants average only 15–30%. When combined with an oral antidepressant, SPRAVATO® has shown remission rates as high as 80% (Wilkinson et al., Nature Reviews Drug Discovery, 2018).

👉 This makes SPRAVATO® therapy at Ketavita a groundbreaking option for individuals struggling with treatment-resistant depression or those in urgent need of fast, effective relief.

Our Philosophy

Prioritizing Safety

We follow FDA guidance and use only approved therapies. While some clinics may use off-label ketamine, we focus exclusively on treatments backed by clinical research.

The Environment Matters

Healing is influenced by surroundings. Our clinic is designed with calming, thoughtful aesthetics to support your well-being throughout treatment.

Simplified Access

We work with your insurance and handle all necessary paperwork.

Collaborative Care

If you’re already working with a therapist or psychiatrist, we ensure full coordination so all aspects of your care work in harmony.

Frequently Asked Questions About Spravato® REMS

Who is eligible for Spravato® treatment?

Spravato may be right for individuals who have tried at least two other antidepressant medications without sufficient relief and continue to experience symptoms of depression.

 

How are the treatments administered?

Spravato is self-administered as a nasal spray under the direct supervision of our medical team. After each dose, patients remain in our clinic for about 2 hours while being closely monitored.

 

How many treatments will I need?

Treatment usually begins with two sessions per week for the first 4 weeks, then is gradually reduced to weekly or biweekly maintenance sessions based on your individual needs.

 

What are the common side effects?

Most side effects are mild and temporary. These may include dizziness, drowsiness, mild dissociation (feeling detached), or a temporary increase in blood pressure. Patients are monitored throughout their session for safety.

 

Can I drive after my session?

No. Due to possible drowsiness or disorientation, you will need a trusted friend or family member to drive you home after each treatment.

Does insurance cover Spravato® therapy?

Some insurance providers may offer partial coverage for Spravato®. Our team can provide documentation and guidance to help you with the reimbursement process.

Â